StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations?
While Nvidia doesn’t develop new therapies, instruments, or reagents, its AI technology powers numerous collaborations with biopharma and lab tools giants stretching back at least five years. The post StockWatch: Amid Nvidia Turmoil, What Happens to Its Life Sciences Collaborations? appeared first on GEN - Genetic Engineering and Biotechnology News .
Nvidia, a leading AI technology company, is facing turmoil following the sudden resignation of its CEO, Jensen Huang, amid reports of up to three extramarital affairs. The board has named Colette Kress, who has served as executive vice president and CFO since 2013, as interim CEO. The company has numerous collaborations with biopharma and lab tools giants, but does not develop therapies or products directly.
The first reported affair raised concerns about national security, as Huang disclosed an extramarital relationship with Alice Huang, founder of Megaspeed International, a customer and AI infrastructure provider. This led to an investigation by Nvidia's board into Huang's relationship with Alice Huang, who may have passed sensitive information to China's Ministry of State Security. Huang's relationship with another Nvidia executive, Kimberly Powell, vice president of healthcare and life sciences, was also reported.
The resignation and reported affairs have caused Nvidia's shares to plummet, with a 32% decline since hitting a record closing price of $239.24 in October. The company's stock has also faced a month-long decline due to investor concerns about the sustainability of funding from tech giants for AI infrastructure. The resignation reveals the challenges businesses face when relying on AI technology, which can have geopolitical implications.
Industry experts are concerned about the future of Nvidia and its relationships with customers, suppliers, and employees. Some, like Alex Zhavoronkov, founder and CEO of Insilico Medicine, expressed hope that the situation would settle without too much drama, while others, like Stacy Rasgon from Bernstein Research, cautioned that there will likely be further news flow and uncertainty about the ability of a new CEO to fill Huang's shoes.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.